C4 Therapeutics Inc (NAS:CCCC)
$ 4.38 -0.43 (-8.94%) Market Cap: 301.37 Mil Enterprise Value: 142.48 Mil PE Ratio: 0 PB Ratio: 1.16 GF Score: 56/100

C4 Therapeutics Inc To Discuss CFT7455 Cohort Clinical Data Call Transcript

Apr 08, 2022 / 06:00PM GMT
Release Date Price: $11.32 (-50.57%)
Operator

Good afternoon. Welcome to the C4 Therapeutics AACR Investor Call on CFT7455 Clinical Data. My name is Vanessa, and I will be your operator for today's call. (Operator Instructions)

I will now turn the call over to Kendra Adams, Senior Vice President, Communications and Investor Relations.

Kendra Adams
C4 Therapeutics, Inc. - SVP of Communications & IR

Good afternoon, everyone, and thank you for joining our call to discuss the clinical data for CFT7455 being presented at AACR. We will be making forward-looking statements today, and Slide 2 contains our legal disclaimer on this matter.

Joining me on the call this afternoon are Andrew Hirsch, our President and CEO; Adam Crystal, our CMO; and Dr. Lonial, an investigator for the CFT7455 Phase I/II trial. Dr. Lonial is a Professor and the Chair of Department of Hematology and Medical Oncology at the Winship Cancer Institute at Emory University. Stew Fisher, our CSO, will also join for the Q&A portion of the call.

I'll turn the call over to Andrew for some introductory remarks.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot